Financial Performance - Revenue for the six months ended June 30, 2022, increased to RMB 438,869,000, up 12.1% from RMB 391,194,000 in the same period of 2021[12] - Gross profit for the six months ended June 30, 2022, was RMB 187,858,000, representing a slight increase of 1.4% compared to RMB 185,303,000 in 2021[12] - Profit from operations for the six months ended June 30, 2022, rose to RMB 28,443,000, an increase of 6.2% from RMB 26,770,000 in the previous year[12] - Profit before taxation for the six months ended June 30, 2022, was RMB 25,281,000, compared to RMB 26,032,000 in the same period of 2021, indicating a decrease of 2.9%[12] - The total comprehensive income for the period attributable to owners of the Company was RMB 20,344,000, up from RMB 19,647,000 in 2021, reflecting an increase of 3.5%[14] - Basic and diluted earnings per share for the six months ended June 30, 2022, were RMB 1.21 cents, compared to RMB 1.17 cents in the same period of 2021, marking a growth of 3.4%[14] Expenses and Costs - Selling and distribution expenses for the six months ended June 30, 2022, were RMB 108,208,000, a decrease of 10.7% from RMB 121,177,000 in 2021[12] - Administrative expenses for the six months ended June 30, 2022, increased to RMB 41,600,000, up from RMB 34,465,000 in the previous year, representing a rise of 20.5%[12] - Other revenue for the six months ended June 30, 2022, was RMB 10,643,000, down from RMB 12,021,000 in 2021, indicating a decline of 11.5%[12] - The Company reported a finance cost of RMB 3,162,000 for the six months ended June 30, 2022, compared to RMB 738,000 in the same period of 2021, reflecting a significant increase of 328.5%[12] Assets and Liabilities - As of June 30, 2022, total assets amounted to RMB 992,845,000, an increase from RMB 972,080,000 as of December 31, 2021, reflecting a growth of approximately 2.8%[18] - Current liabilities increased to RMB 339,318,000 from RMB 335,490,000, indicating a slight rise of about 0.5%[18] - Net current assets improved to RMB 434,767,000, up from RMB 404,489,000, representing an increase of approximately 7.5%[18] - Total equity reached RMB 962,235,000, compared to RMB 944,400,000 at the end of 2021, marking a growth of about 1.9%[20] - The company's retained earnings rose to RMB 266,279,000, up from RMB 245,935,000, reflecting an increase of approximately 8.3%[23] - Trade and other payables increased to RMB 243,154,000 from RMB 206,449,000, showing a significant rise of about 17.7%[18] - Inventories grew to RMB 175,182,000, compared to RMB 157,954,000, indicating an increase of approximately 10.9%[18] - Interest-bearing bank borrowings decreased to RMB 66,070,000 from RMB 101,137,000, a reduction of about 34.7%[18] Cash Flow - Operating cash flows before changes in working capital increased to RMB 50,567,000 in 2022 from RMB 37,856,000 in 2021, representing a growth of 33.5%[26] - Net cash generated from operating activities was RMB 64,462,000 in 2022, compared to a net cash used of RMB 65,036,000 in 2021, indicating a significant turnaround[26] - Cash generated from operations, after income tax paid, was RMB 68,663,000, with income tax paid amounting to RMB 4,201,000[26] - Net cash generated from investing activities was RMB 17,240,000 in 2022, a recovery from a net cash used of RMB 64,412,000 in 2021[28] - The company reported a net cash used in financing activities of RMB 41,589,000 in 2022, compared to RMB 20,481,000 in 2021, indicating increased financing costs[28] - Cash and cash equivalents at the end of the period increased to RMB 267,257,000 in 2022 from RMB 261,956,000 in 2021, showing a slight growth[28] Revenue Breakdown - Revenue from the manufacturing and selling of medicines reached RMB 310,182,000 for the six months ended June 30, 2022, an increase of 32.5% compared to RMB 233,766,000 for the same period in 2021[44] - Revenue from sales and distribution of medicines and healthcare products was RMB 128,687,000 for the six months ended June 30, 2022, compared to RMB 157,428,000 in the same period of 2021, showing a decline of 18.3%[44] - The total revenue for the three months ended June 30, 2022, was RMB 223,171,000, an increase of 30% from RMB 171,905,000 in the same period of 2021[44] - Reportable segment revenue for the six months ended June 30, 2022, was RMB 461,618,000, an increase from RMB 412,103,000 in 2021, representing a growth of 12%[60] - Revenue from external customers in the manufacturing and selling of medicines segment was RMB 310,182,000 for the first half of 2022, compared to RMB 233,766,000 in 2021, marking a 32.6% increase[51] Research and Development - Research and development costs for the six months ended June 30, 2022, were RMB 6,592,000, slightly up from RMB 6,082,000 in the same period of 2021, showing an increase of approximately 8.4%[79] - The Group is entitled to claim 175% of the research and development expenses as tax-deductible expenses under the "Super Deduction" policy, applicable to three subsidiaries[87] Related Party Transactions - Related party transactions for the six months ended June 30, 2022, included sales of goods amounting to RMB 5,800,000 with Shandong Neptunus Yinhe Pharmaceutical Company Limited[125] - The company’s related party transactions were conducted under normal business terms, consistent with those charged to third-party suppliers and customers[146] Future Outlook - The company expects revenue guidance for Q3 2023 to be between $5.5 billion and $5.7 billion, indicating a potential growth of 6% to 9%[200] - The company plans to enter the Asian market by Q4 2023, targeting a revenue contribution of $1 billion in the first year[200]
海王英特龙(08329) - 2022 - 中期财报